Sachin Laddha

Dr. Sachin Laddha


Research Focus & Metrics

Academic Career Length

21Years (2006-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 October 2009 in Bioorganic & Medicinal Chemistry
Verified
Journal Article
Closed access
SLSachin Laddha
Sachin Laddha
SBSatyendra P. Bhatnagar
Satyendra P. Bhatnagar


4 August 2008 in Phosphorus, Sulfur, and Silicon and the Related Elements
Verified
Journal Article
Closed access
SLSachin Laddha
Sachin Laddha
SBSatyendra P. Bhatnagar
Satyendra P. Bhatnagar
A fast and highly efficient microwave accelerated solution phase procedure for the synthesis of a series of 2-phenyl-3-(benzothiazol-2-yl)-4[3H]-quinazolinones, substituted in the benzothiazole ring, is developed. The title compounds were characterized by elemental analyses, IR, 1H NMR, and EI-MS data. The anticonvulsant activity of all the new compounds (3a-m and 4a-m) was evaluated against Maximum Electroshock (MES) induced seizures and against subcutaneous pentylenetetrazole (PTZ) induced seizures model in mice. The neurotoxicity was assessed using the Rotorod procedure. All the compounds tested were administered intraperitoneally at a various dose levels ranging from 7-200 mg/Kg body weight and the median toxic dose (TD50) and the protection index (PI) values were determined. In general compounds 3a-m were found to be more potent compared to compounds 4a-m. Among the compound tested, the compound 3e in the 2-phenyl-3-(benzothiazole-2-yl)-4[3H]-quinazolinone series and 4l in the 6,8-dibromo-2-phenyl-3-(benzothiazole-2-yl)-4[3H]-quinazolinone series were found to be the most potent.

30 September 2008 in Medicinal Chemistry Research
Verified
Journal Article
Closed access
PDF file
SLSachin Laddha
Sachin Laddha
SWSudhir G. Wadodkar
Sudhir G. Wadodkar
SMSharad K. Meghal
Sharad K. Meghal

6 April 2010 in Future Medicinal Chemistry
Verified
Journal Article
Closed access
SLSachin Laddha
Sachin Laddha
SBSatyendra P Bhatnagar
Satyendra P Bhatnagar
Epilepsy is one of the most common neurological disorders, affecting approximately 1% of the world's population. The currently available anticonvulsants are effective in reducing the severity and number of seizures in less than 70% of patients. Moreover, their use is associated with undesirable side effects, ranging from cosmetic (gingival hyperplasia) to life-threatening (hepatotoxicity or megaloblastic anemia). Therefore, the continued search for safer and more effective anti-epileptic drugs is both urgent and necessary. A survey of the literature reveals that various derivatives of quinazolinone, thienopyrimidine and pyridopyrimidine have shown very promising anticonvulsant activity, along with other pharmacological activities. We therefore decided to concentrate our efforts on screening novel quinazolinone fused with thienopyrimidine/pyridopyrimidine. A novel series of 1,2,9,11-tetrasubstituted-7H-thieno[2´,3´:4,5]pyrimido[6,1-b]-quinazolin-7-ones and 1,3,10,12-tetrasubstituted-8H-pyrido[2´,3´:4,5]pyrimido[6,1-b]quinazolin-8-ones were synthesized by the method reported. The anticonvulsant activity of all the new compounds was evaluated against maximum electroshock-induced seizures and against subcutaneous pentylenetetrazole (scPTZ)-induced seizure models in mice. The neurotoxicity was assessed using the Rotorod procedure. All the compounds tested were administered intraperitoneally at a various dose levels ranging from 15 to 175 mg/kg body weight, and the median toxic dose (TD(50)) and the protection index values were determined. All compounds tested exhibited good activity. The structure-activity relationships based on the results obtained for these series were also studied. This study indicates that fused quinazolinones display very good anticonvulsant activity. In both series, electron-withdrawing substitutions showed more activity. Among all the compounds tested, 10,12-dibromo-1- (4-chloro-phenyl)-3- (4-tolyl)-8H-pyrido[2´,3´:4,5]pyrimido[6,1-b]quinazolin-8-one and 10,12-dibromo-3- (4-chloro-phenyl)-1-phenyl-8H-pyrido[2´,3´:4,5]pyrimido[6,1-b]quinazolin-8-one were found to be the most potent.

26 October 2007 in Arkivoc
Verified
Journal Article
Open access
SLSachin Laddha
Sachin Laddha
SBSatayendra P. Bhatnagar
Satayendra P. Bhatnagar